DNA Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1830214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-33.1%
TTM net income YoY26.1%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-242.5%
Net margin-249.2%
FCF margin-172.3%
EBITDA margin-190.5%
Returns
ROE-52.7%
ROA-23.5%
ROIC (approx.)-51.0%
Asset turnover0.09x
Leverage & solvency
Liabilities / assets58.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue6.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $170.16M | $227.04M |
| R&D expense | $243.77M | $424.06M |
| SG&A expense | $183.29M | $246.16M |
| Operating income | -$315.28M | -$559.76M |
| Interest expense | $0 | $94,000 |
| Pretax income | -$313.60M | -$547.51M |
| Income tax | -$837,000 | -$479,000 |
| Net income | -$312.76M | -$547.03M |
| EBITDA | -$256.29M | -$496.74M |
| EPS (basic) | -5.64 | -10.54 |
| EPS (diluted) | -5.64 | -10.54 |
| Weighted avg. shares (diluted) | 55.46M | 51.89M |
| Banking | ||
| Loans, net | $9.70M | $25.10M |
| Balance sheet | ||
| Cash & equivalents | $167.20M | $561.57M |
| Short-term investments | $255.42M | $0 |
| Receivables | $24.03M | $21.86M |
| Current assets | $471.84M | $602.74M |
| PP&E, net | $167.37M | $203.72M |
| Goodwill | — | $0 |
| Intangibles | $53.48M | $72.51M |
| Total assets | $1.12B | $1.38B |
| Current liabilities | $95.97M | $107.27M |
| Total liabilities | $611.11M | $661.39M |
| Shareholders' equity | $508.59M | $716.06M |
| Shares outstanding | 58.21M | 54.37M |
| Cash flow statement | ||
| Operating cash flow | -$171.06M | -$319.58M |
| Capital expenditure | $7.67M | $62.54M |
| Free cash flow | -$178.72M | -$382.13M |
| Investing cash flow | -$240.29M | -$62.24M |
| Financing cash flow | $17.77M | -$1.74M |
| Depreciation & amortization | $58.99M | $63.02M |
| Stock-based compensation | $81.55M | $112.34M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.